Literature DB >> 18413778

Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model.

Naoko Kobayashi1, R James Barnard, Jonathan Said, Jenny Hong-Gonzalez, Dan M Corman, Melvin Ku, Ngan Bao Doan, Dorina Gui, David Elashoff, Pinchas Cohen, William J Aronson.   

Abstract

This study evaluated the effect of dietary fat on prostate cancer development by using the Hi-Myc mouse transgenic prostate cancer model. Hi-Myc mice develop murine prostatic intraepithelial neoplasia (mPIN) as early as 2 to 4 weeks and invasive adenocarcinoma between 6 and 9 months due to the overexpression of human c-Myc in the mouse prostate. Three-week-old male Hi-Myc mice were placed on high-fat (HF; 42% Kcal) or low-fat (LF; 12% Kcal) diets, and equal caloric intake was maintained until euthanasia at 7 months. The number of mice that developed invasive adenocarcinoma at 7 months was 27% less in the LF diet group (12/28) compared with the HF diet group (23/33, P < 0.05). Epithelial cells in mPIN lesions in the LF group had a significantly lower proliferative index compared with epithelial cells in the HF group (21.7% versus 28.9%, P < 0.05). During the mPIN phase of carcinogenesis (4 months), the LF group had higher serum insulin-like growth factor (IGF) binding protein-1 levels (21.0 +/- 8.9 ng/mL versus 3.2 +/- 0.8 ng/mL, P < 0.05) relative to the HF group. Akt (Ser(473)) phosphorylation, Akt kinase activity, and phosphorylation of downstream targets of Akt in prostates were significantly reduced in the LF diet group compared with the HF group. We conclude that dietary fat reduction delays transition from mPIN to invasive cancer in this Myc-driven transgenic mouse model, possibly through suppression of the IGF-Akt pathway and decreased proliferation of mPIN epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413778      PMCID: PMC2902987          DOI: 10.1158/0008-5472.CAN-07-5616

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone.

Authors:  Shoshana Yakar; Mary L Bouxsein; Ernesto Canalis; Hui Sun; Vaida Glatt; Caren Gundberg; Pinchas Cohen; David Hwang; Yves Boisclair; Derek Leroith; Clifford J Rosen
Journal:  J Endocrinol       Date:  2006-05       Impact factor: 4.286

Review 2.  Role of the insulin-like growth factor family in cancer development and progression.

Authors:  H Yu; T Rohan
Journal:  J Natl Cancer Inst       Date:  2000-09-20       Impact factor: 13.506

3.  Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Authors:  P Stattin; A Bylund; S Rinaldi; C Biessy; H Déchaud; U H Stenman; L Egevad; E Riboli; G Hallmans; R Kaaks
Journal:  J Natl Cancer Inst       Date:  2000-12-06       Impact factor: 13.506

4.  Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.

Authors:  S Aaltomaa; V Kärjä; P Lipponen; T Isotalo; J P Kankkunen; M Talja; R Mokka
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

5.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.

Authors:  Mei-Ling Chen; Pei-Zhang Xu; Xiao-ding Peng; William S Chen; Grace Guzman; Ximing Yang; Antonio Di Cristofano; Pier Paolo Pandolfi; Nissim Hay
Journal:  Genes Dev       Date:  2006-06-15       Impact factor: 11.361

6.  Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone.

Authors:  M Drobnjak; I Osman; H I Scher; M Fazzari; C Cordon-Cardo
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

7.  Correlation of increased apoptosis and proliferation with development of prostatic intraepithelial neoplasia (PIN) in ventral prostate of the Noble rat.

Authors:  W Xie; Y C Wong; S W Tsao
Journal:  Prostate       Date:  2000-06-15       Impact factor: 4.104

Review 8.  Cyclooxygenases, prostanoids, and tumor progression.

Authors:  Man-Tzu Wang; Kenneth V Honn; Daotai Nie
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

9.  Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids.

Authors:  Isabelle M Berquin; Younong Min; Ruping Wu; Jiansheng Wu; Donna Perry; J Mark Cline; Mike J Thomas; Todd Thornburg; George Kulik; Adrienne Smith; Iris J Edwards; Ralph D'Agostino; Hao Zhang; Hong Wu; Jing X Kang; Yong Q Chen
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

10.  Impact of differential cyclin D1 expression and localisation in prostate cancer.

Authors:  C E S Comstock; M P Revelo; C R Buncher; K E Knudsen
Journal:  Br J Cancer       Date:  2007-03-26       Impact factor: 7.640

View more
  45 in total

1.  Dietary energy balance modulates prostate cancer progression in Hi-Myc mice.

Authors:  Jorge Blando; Tricia Moore; Stephen Hursting; Guiyu Jiang; Achinto Saha; Linda Beltran; Jianjun Shen; John Repass; Sara Strom; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-27

Review 2.  Diet and prostate cancer: mechanisms of action and implications for chemoprevention.

Authors:  Vasundara Venkateswaran; Laurence H Klotz
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

3.  Glutaminolysis and carcinogenesis of oral squamous cell carcinoma.

Authors:  Marcel Cetindis; Thorsten Biegner; Adelheid Munz; Peter Teriete; Siegmar Reinert; Martin Grimm
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-07       Impact factor: 2.503

Review 4.  Adipocyte and lipid metabolism in cancer drug resistance.

Authors:  Yihai Cao
Journal:  J Clin Invest       Date:  2019-07-02       Impact factor: 14.808

5.  Dietary intake and prostate cancer, continued pursuit for evidence.

Authors:  Pao-Hwa Lin; Stephen J Freedland
Journal:  Transl Androl Urol       Date:  2019-07

6.  Lipid catabolism via CPT1 as a therapeutic target for prostate cancer.

Authors:  Isabel R Schlaepfer; Leah Rider; Lindsey Ulkus Rodrigues; Miguel A Gijón; Colton T Pac; Lina Romero; Adela Cimic; S Joseph Sirintrapun; L Michael Glodé; Robert H Eckel; Scott D Cramer
Journal:  Mol Cancer Ther       Date:  2014-08-13       Impact factor: 6.261

7.  Chemoprevention of prostate cancer with lycopene in the TRAMP model.

Authors:  Ramdev Konijeti; Susanne Henning; Aune Moro; Ahmed Sheikh; David Elashoff; Ari Shapiro; Melvin Ku; Jonathan W Said; David Heber; Pinchas Cohen; William J Aronson
Journal:  Prostate       Date:  2010-10-01       Impact factor: 4.104

8.  The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model.

Authors:  Jorge Caso; Elizabeth M Masko; Jean A Thomas Ii; Susan H Poulton; Mark Dewhirst; Salvatore V Pizzo; Stephen J Freedland
Journal:  Prostate       Date:  2012-10-04       Impact factor: 4.104

Review 9.  Bioactive food components and cancer-specific metabonomic profiles.

Authors:  Young S Kim; John A Milner
Journal:  J Biomed Biotechnol       Date:  2010-11-11

Review 10.  The relationship between nutrition and prostate cancer: is more always better?

Authors:  Elizabeth M Masko; Emma H Allott; Stephen J Freedland
Journal:  Eur Urol       Date:  2012-11-15       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.